Genprex shares surge 21.8% intraday on Congressman Moore's investment and FDA meeting for REQORSA trials.

Genprex Inc. surged 21.79% intraday after Congressman Tim Moore’s investment of $31,000–$115,000 in the company and positive developments surrounding its lead drug candidate, REQORSA. The investment, coupled with the company’s upcoming FDA meeting to request Investigational New Drug (IND) studies for human clinical trials, signaled strong confidence in its pipeline. These events, alongside social media-driven optimism over preclinical data for diabetes therapy GPX-002 and Nasdaq compliance relief, fueled heightened investor interest. The stock’s volatility and sharp intraday gain reflect immediate market reaction to regulatory progress and institutional backing, positioning Genprex for potential clinical milestones in oncology and diabetes.